CTOs on the Move

Oklahoma Blood Institute

www.obi.org

 
Oklahoma Blood Institute is the ninth largest, non profit blood center in America. More than 125,000 donors provide more than 250,000 gifts of blood yearly for transfusion and associated clinical services. OBI employs nearly 700 Oklahomans and works with an estimated 800 volunteers and 2,600 drive coordinators
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million
  • www.obi.org
  • 1001 N Lincoln Blvd
    Oklahoma City, OK USA 73104
  • Phone: 405.297.5700

Executives

Name Title Contact Details
Rick Hensley
Director of Risk Management and Physical Security Profile
John Marcellus
Director of Information Technology Operations Profile

Similar Companies

Quick Weight Loss Centers

Quick Weight Loss Centers is a leading multi-state health and wellness company that provides highly differentiated weight loss management services. The company offers its program through both an in-center and digitally for clients not located in geographies with center locations.

delta flex travelers

delta flex travelers is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Knox Community Hospital

Knox Community Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Knox Community Hospital is based in Mount Vernon, OH. You can find more information on Knox Community Hospital at www.knoxcommhosp.org

PreMark Health Science

PreMark Health ScienceNutraceutical and cosmeceutical products and packaging. PreMark provides end-to-end product solutions for nutrition and personal care products, from product development and formulation, to blending, manufacturing and packaging. Co...

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.